CDXC ChromaDex: Earnings per share for the trailing year

Automation of supplement synthesis and packaging allows ChromaDex Corporation (CDXC) to optimize staffing during high-volume periods. The TTM annual net income per share growth reflects development inertia, with the metric holding around 71.20. Prospects are based on NAD+ patents and retail reach, while stability is guaranteed by operating exclusively within the US without external political risks.
CDXC (ChromaDex Corp): analytical breakdowns and indicator data

ChromaDex Corporation (CDXC) retains leading biochemists through a system of patent bonuses and stock options. The efficiency of such investments in human capital is reflected in the annual shift of EPS TTM, which measures the net profit per share dynamics over the last twelve months. Growth in this metric confirms the monetization of scientific developments in the NAD+ field. A fading trend on the chart signals a slowdown in profitability rates, which is critical for assessing the fair value of capital.